| Creative Community Mental Health Inc | |
|
381 N Krome Ave Ste 206 Homestead FL 33030-6047 | |
| (786) 601-9202 | |
| (786) 668-6398 |
| Full Name | Creative Community Mental Health Inc |
|---|---|
| Speciality | Clinic/Center |
| Location | 381 N Krome Ave Ste 206, Homestead, Florida |
| Authorized Official Name and Position | Annette Figarola (AUTHORIZED OFFICAL) |
| Authorized Official Contact | 3059924008 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Creative Community Mental Health Inc 381 N Krome Ave Ste 206 Homestead FL 33030-6047 Ph: (786) 601-9202 | Creative Community Mental Health Inc 381 N Krome Ave Ste 206 Homestead FL 33030-6047 Ph: (786) 601-9202 |
| NPI Number | 1023677432 |
|---|---|
| Provider Enumeration Date | 06/10/2019 |
| Last Update Date | 04/29/2022 |
| Certification Date | 04/29/2022 |
| Medicare PECOS PAC ID | 1456772664 |
|---|---|
| Medicare Enrollment ID | O20200526001405 |
News Archive
Testing for breast cancer risk was the subject of remarks by two featured speakers at a recent congressional reception on Capitol Hill. The event generated momentum to pass the EARLY Act and raise awareness about breast cancer in young adult women.
African "heads of state gathered in Ethiopia's capital Addis Ababa for the African Union Summit met at a side event on Sunday, Jan. 27 to renew their commitment to reducing the maternal mortality rate on the continent," Inter Press Service reports.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, today announced receipt of the final $2.0 million payment from Kaketsuken under the $8.0 million collaboration announced in November 2009. The agreement involves multiple proprietary XOMA antibody research and development technologies, including a new XOMA phage display library, and a suite of integrated information and data management systems.
Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that combination treatment with milatuzumab, the first humanized anti-CD74 antibody in clinical testing, and veltuzumab, a second-generation humanized anti-CD20 antibody, resulted in therapeutic responses in heavily pretreated and rituximab-refractory non-Hodgkin's lymphoma patients.
The results from a new study by neurological researchers from the Rush Alzheimer's Disease Center at Rush University Medical Center suggest that people who were emotionally neglected as children may have a higher risk of stroke in later adulthood.
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023677432 | NPI | - | NPPES |
| 1023677432 | Medicaid | FL |
| Provider Name | Lazaro H Cordoves |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1821126079 PECOS PAC ID: 9133139009 Enrollment ID: I20060424000159 |
News Archive
Testing for breast cancer risk was the subject of remarks by two featured speakers at a recent congressional reception on Capitol Hill. The event generated momentum to pass the EARLY Act and raise awareness about breast cancer in young adult women.
African "heads of state gathered in Ethiopia's capital Addis Ababa for the African Union Summit met at a side event on Sunday, Jan. 27 to renew their commitment to reducing the maternal mortality rate on the continent," Inter Press Service reports.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, today announced receipt of the final $2.0 million payment from Kaketsuken under the $8.0 million collaboration announced in November 2009. The agreement involves multiple proprietary XOMA antibody research and development technologies, including a new XOMA phage display library, and a suite of integrated information and data management systems.
Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that combination treatment with milatuzumab, the first humanized anti-CD74 antibody in clinical testing, and veltuzumab, a second-generation humanized anti-CD20 antibody, resulted in therapeutic responses in heavily pretreated and rituximab-refractory non-Hodgkin's lymphoma patients.
The results from a new study by neurological researchers from the Rush Alzheimer's Disease Center at Rush University Medical Center suggest that people who were emotionally neglected as children may have a higher risk of stroke in later adulthood.
› Verified 4 days ago
| Provider Name | Amanda Allison |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1831695105 PECOS PAC ID: 1557738432 Enrollment ID: I20221103002104 |
News Archive
Testing for breast cancer risk was the subject of remarks by two featured speakers at a recent congressional reception on Capitol Hill. The event generated momentum to pass the EARLY Act and raise awareness about breast cancer in young adult women.
African "heads of state gathered in Ethiopia's capital Addis Ababa for the African Union Summit met at a side event on Sunday, Jan. 27 to renew their commitment to reducing the maternal mortality rate on the continent," Inter Press Service reports.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, today announced receipt of the final $2.0 million payment from Kaketsuken under the $8.0 million collaboration announced in November 2009. The agreement involves multiple proprietary XOMA antibody research and development technologies, including a new XOMA phage display library, and a suite of integrated information and data management systems.
Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that combination treatment with milatuzumab, the first humanized anti-CD74 antibody in clinical testing, and veltuzumab, a second-generation humanized anti-CD20 antibody, resulted in therapeutic responses in heavily pretreated and rituximab-refractory non-Hodgkin's lymphoma patients.
The results from a new study by neurological researchers from the Rush Alzheimer's Disease Center at Rush University Medical Center suggest that people who were emotionally neglected as children may have a higher risk of stroke in later adulthood.
› Verified 4 days ago
News Archive
Testing for breast cancer risk was the subject of remarks by two featured speakers at a recent congressional reception on Capitol Hill. The event generated momentum to pass the EARLY Act and raise awareness about breast cancer in young adult women.
African "heads of state gathered in Ethiopia's capital Addis Ababa for the African Union Summit met at a side event on Sunday, Jan. 27 to renew their commitment to reducing the maternal mortality rate on the continent," Inter Press Service reports.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, today announced receipt of the final $2.0 million payment from Kaketsuken under the $8.0 million collaboration announced in November 2009. The agreement involves multiple proprietary XOMA antibody research and development technologies, including a new XOMA phage display library, and a suite of integrated information and data management systems.
Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that combination treatment with milatuzumab, the first humanized anti-CD74 antibody in clinical testing, and veltuzumab, a second-generation humanized anti-CD20 antibody, resulted in therapeutic responses in heavily pretreated and rituximab-refractory non-Hodgkin's lymphoma patients.
The results from a new study by neurological researchers from the Rush Alzheimer's Disease Center at Rush University Medical Center suggest that people who were emotionally neglected as children may have a higher risk of stroke in later adulthood.
› Verified 4 days ago
Devonear Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 950 N Krome Ave Ste 405, Homestead, FL 33030 Phone: 305-246-0210 Fax: 305-246-0310 | |
Leap Home Care Services, Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 25343 Sw 121st Ct, Homestead, FL 33032 Phone: 786-406-2937 | |
Bright Start Aba Services 2 Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 15041 Sw 299th St, Homestead, FL 33033 Phone: 786-315-8971 | |
Ramirez Alejo Health Care Service Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1621 Nw 14th Ave, Homestead, FL 33030 Phone: 786-710-4665 | |
Homestead Aba Services Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 541 Se 34th Ter, Homestead, FL 33033 Phone: 305-397-3815 | |
Positive Insights Behavioral Health Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 100 Ne 15th St, Homestead, FL 33030 Phone: 786-600-4388 |